Design and biological assessment of membrane-tethering neuroprotective peptides derived from the pituitary adenylate cyclase-activating polypeptide type 1 receptor

Add time:09/01/2019    Source:sciencedirect.com

BackgroundThe pituitary adenylate cyclase-activating polypeptide (PACAP) type 1 receptor (PAC1), a class B G protein-coupled receptor (GPCR), has emerged as a promising target for treating neurodegenerative conditions. Unfortunately, despite years of research, no PAC1-specific agonist has been discovered, as activity on two other GPCRs, VPAC1 and VPAC2, is retained with current analogs. Cell signaling is related to structural modifications in the intracellular loops (ICLs) of GPCRs. Thus, we hypothesized that peptides derived from the ICLs (called pepducins) of PAC1 might initiate, as allosteric ligands, signaling cascades after recognition of the parent receptor and modulation of its conformational landscape.

We also recommend Trading Suppliers and Manufacturers of PITUITARY ADENYLATE CYCLASE ACTIVATING (cas 136134-68-4). Pls Click Website Link as below: cas 136134-68-4 suppliers

Prev:Pituitary adenylate cyclase-activating polypeptide: Postnatal development in multiple brain stem respiratory-related nuclei in the rat
Next:Full Length ArticleProtective effects of PITUITARY ADENYLATE CYCLASE ACTIVATING (cas 136134-68-4) polypeptide against neurotoxic agents)